15 results on '"Caroline L. Ashley"'
Search Results
2. Statement in Support of: 'Virology under the Microscope—a Call for Rational Discourse'
- Author
-
Peter Speck, Jason Mackenzie, Rowena A. Bull, Barry Slobedman, Heidi Drummer, Johanna Fraser, Lara Herrero, Karla Helbig, Sarah Londrigan, Gregory Moseley, Natalie Prow, Grant Hansman, Robert Edwards, Chantelle Ahlenstiel, Allison Abendroth, David Tscharke, Jody Hobson-Peters, Robson Kriiger-Loterio, Rhys Parry, Glenn Marsh, Emma Harding, David A. Jacques, Matthew J. Gartner, Wen Shi Lee, Julie McAuley, Paola Vaz, Frank Sainsbury, Michelle D. Tate, Jane Sinclair, Allison Imrie, Stephen Rawlinson, Andrew Harman, Jillian M. Carr, Ebony A. Monson, Merilyn Hibma, Timothy J. Mahony, Thomas Tu, Robert J. Center, Lok Bahadur Shrestha, Robyn Hall, Morgyn Warner, Vernon Ward, Danielle E. Anderson, Nicholas S. Eyre, Natalie E. Netzler, Alison J. Peel, Peter Revill, Michael Beard, Alistair R. Legione, Alexandra J. Spencer, Adi Idris, Jade Forwood, Subir Sarker, Damian F. J. Purcell, Nathan Bartlett, Joshua M. Deerain, Bruce J. Brew, Sassan Asgari, Helen Farrell, Alexander Khromykh, Daniel Enosi Tuipulotu, David Anderson, Sevim Mese, Yaman Tayyar, Kathryn Edenborough, Jasim Muhammad Uddin, Abrar Hussain, Connor J. I. Daymond, Jacinta Agius, Karyn N. Johnson, Paniz Shirmast, Mahdi Abedinzadeshahri, Robin MacDiarmid, Caroline L. Ashley, Jay Laws, Lucy L. Furfaro, Thomas D. Burton, Stephen M. R. Johnson, Zahra Telikani, Mary Petrone, Justin A. Roby, Carolyn Samer, Andreas Suhrbier, April Van Der Kamp, Anthony Cunningham, Celeste Donato, Jackie Mahar, Wesley D. Black, Subhash Vasudevan, Roman Lenchine, Kirsten Spann, Daniel J. Rawle, Penny Rudd, Jessica Neil, Richard Kingston, Timothy P. Newsome, Ki Wook Kim, Johnson Mak, Kym Lowry, Nathan Bryant, Joanne Meers, Jason A. Roberts, Nigel McMillan, Larisa I. Labzin, Andrii Slonchak, Leon E. Hugo, Bennett Henzeler, Natalee D. Newton, Cassandra T. David, Patrick C. Reading, Camille Esneau, Tatiana Briody, Najla Nasr, Donna McNeale, Brian McSharry, Omid Fakhri, Bethany A. Horsburgh, Grant Logan, Paul Howley, and Paul Young
- Subjects
COVID-19 ,SARS-CoV2 ,biosafety ,coronavirus ,gain of function ,pandemic ,Microbiology ,QR1-502 - Published
- 2023
- Full Text
- View/download PDF
3. Suppression of MR1 by human cytomegalovirus inhibits MAIT cell activation
- Author
-
Caroline L. Ashley, Brian P. McSharry, Hamish E. G. McWilliam, Richard J. Stanton, Ceri A. Fielding, Rommel A. Mathias, David P. Fairlie, James McCluskey, Jose A. Villadangos, Jamie Rossjohn, Allison Abendroth, and Barry Slobedman
- Subjects
human cytomegalovirus ,herpesvirus ,MHC class I related protein-1 ,MR1 ,mucosal-associated invariant T cells ,MAIT cells ,Immunologic diseases. Allergy ,RC581-607 - Abstract
IntroductionThe antigen presentation molecule MHC class I related protein-1 (MR1) is best characterized by its ability to present bacterially derived metabolites of vitamin B2 biosynthesis to mucosal-associated invariant T-cells (MAIT cells).MethodsThrough in vitro human cytomegalovirus (HCMV) infection in the presence of MR1 ligand we investigate the modulation of MR1 expression. Using coimmunoprecipitation, mass spectrometry, expression by recombinant adenovirus and HCMV deletion mutants we investigate HCMV gpUS9 and its family members as potential regulators of MR1 expression. The functional consequences of MR1 modulation by HCMV infection are explored in coculture activation assays with either Jurkat cells engineered to express the MAIT cell TCR or primary MAIT cells. MR1 dependence in these activation assays is established by addition of MR1 neutralizing antibody and CRISPR/Cas-9 mediated MR1 knockout.ResultsHere we demonstrate that HCMV infection efficiently suppresses MR1 surface expression and reduces total MR1 protein levels. Expression of the viral glycoprotein gpUS9 in isolation could reduce both cell surface and total MR1 levels, with analysis of a specific US9 HCMV deletion mutant suggesting that the virus can target MR1 using multiple mechanisms. Functional assays with primary MAIT cells demonstrated the ability of HCMV infection to inhibit bacterially driven, MR1-dependent activation using both neutralizing antibodies and engineered MR1 knockout cells.DiscussionThis study identifies a strategy encoded by HCMV to disrupt the MR1:MAIT cell axis. This immune axis is less well characterized in the context of viral infection. HCMV encodes hundreds of proteins, some of which regulate the expression of antigen presentation molecules. However the ability of this virus to regulate the MR1:MAIT TCR axis has not been studied in detail.
- Published
- 2023
- Full Text
- View/download PDF
4. Assessing the suitability of long non-coding RNAs as therapeutic targets and biomarkers in SARS-CoV-2 infection
- Author
-
Yichen Zhong, Caroline L. Ashley, Megan Steain, and Sandro Fernandes Ataide
- Subjects
COVID-19 ,SARS-CoV-2 ,cytokine release syndrome ,lncRNA profiling ,NLRP3 inflammasome ,IL-6 ,Biology (General) ,QH301-705.5 - Abstract
Long non-coding RNAs (lncRNAs) are RNA transcripts that are over 200 nucleotides and rarely encode proteins or peptides. They regulate gene expression and protein activities and are heavily involved in many cellular processes such as cytokine secretion in respond to viral infection. In severe COVID-19 cases, hyperactivation of the immune system may cause an abnormally sharp increase in pro-inflammatory cytokines, known as cytokine release syndrome (CRS), which leads to severe tissue damage or even organ failure, raising COVID-19 mortality rate. In this review, we assessed the correlation between lncRNAs expression and cytokine release syndrome by comparing lncRNA profiles between COVID-19 patients and health controls, as well as between severe and non-severe cases. We also discussed the role of lncRNAs in CRS contributors and showed that the lncRNA profiles display consistency with patients’ clinic symptoms, thus suggesting the potential of lncRNAs as drug targets or biomarkers in COVID-19 treatment.
- Published
- 2022
- Full Text
- View/download PDF
5. Discovery of Cyclic Peptide Ligands to the SARS-CoV‑2 Spike Protein Using mRNA Display
- Author
-
Alexander Norman, Charlotte Franck, Mary Christie, Paige M. E. Hawkins, Karishma Patel, Anneliese S. Ashhurst, Anupriya Aggarwal, Jason K. K. Low, Rezwan Siddiquee, Caroline L. Ashley, Megan Steain, James A. Triccas, Stuart Turville, Joel P. Mackay, Toby Passioura, and Richard J. Payne
- Subjects
Chemistry ,QD1-999 - Published
- 2021
- Full Text
- View/download PDF
6. Virus-Mediated Suppression of the Antigen Presentation Molecule MR1
- Author
-
Brian P. McSharry, Carolyn Samer, Hamish E.G. McWilliam, Caroline L. Ashley, Michael B. Yee, Megan Steain, Ligong Liu, David P. Fairlie, Paul R. Kinchington, James McCluskey, Allison Abendroth, Jose A. Villadangos, Jamie Rossjohn, and Barry Slobedman
- Subjects
Biology (General) ,QH301-705.5 - Abstract
Summary: The antigen-presenting molecule MR1 presents microbial metabolites related to vitamin B2 biosynthesis to mucosal-associated invariant T cells (MAIT cells). Although bacteria and fungi drive the MR1 biosynthesis pathway, viruses have not previously been implicated in MR1 expression or its antigen presentation. We demonstrate that several herpesviruses inhibit MR1 cell surface upregulation, including a potent inhibition by herpes simplex virus type 1 (HSV-1). This virus profoundly suppresses MR1 cell surface expression and targets the molecule for proteasomal degradation, whereas ligand-induced cell surface expression of MR1 prior to infection enables MR1 to escape HSV-1-dependent targeting. HSV-1 downregulation of MR1 is dependent on de novo viral gene expression, and we identify the Us3 viral gene product as functioning to target MR1. Furthermore, HSV-1 downregulation of MR1 disrupts MAIT T cell receptor (TCR) activation. Accordingly, virus-mediated targeting of MR1 defines an immunomodulatory strategy that functionally disrupts the MR1-MAIT TCR axis. : The antigen-presenting molecule MR1 presents bacterial and fungal metabolites to MAIT cells. McSharry et al. show that the herpesviruses HSV-1 and CMV disrupt MR1 expression. Downregulation of MR1 by HSV-1 inhibits bacterially driven MAIT TCR-dependent activation. This provides evidence of virus immunomodulatory control of the MR1-restricted immune response. Keywords: herpesvirus, herpes simplex virus, cytomegalovirus, MR1, MAIT cell, immune evasion, virus targeting of MHC I-like molecules
- Published
- 2020
- Full Text
- View/download PDF
7. Interferon-Independent Innate Responses to Cytomegalovirus
- Author
-
Caroline L. Ashley, Allison Abendroth, Brian P. McSharry, and Barry Slobedman
- Subjects
interferon ,cytomegalovirus ,IFN-independent ,ISG ,herpes ,innate immunity ,Immunologic diseases. Allergy ,RC581-607 - Abstract
The critical role of interferons (IFNs) in mediating the innate immune response to cytomegalovirus (CMV) infection is well established. However, in recent years the functional importance of the IFN-independent antiviral response has become clearer. IFN-independent, IFN regulatory factor 3 (IRF3)-dependent interferon-stimulated gene (ISG) regulation in the context of CMV infection was first documented 20 years ago. Since then several IFN-independent, IRF3-dependent ISGs have been characterized and found to be among the most influential in the innate response to CMV. These include virus inhibitory protein, endoplasmic reticulum-associated IFN-inducible (viperin), ISG15, members of the interferon inducible protein with tetratricopeptide repeats (IFIT) family, interferon-inducible transmembrane (IFITM) proteins and myxovirus resistance proteins A and B (MxA, MxB). IRF3-independent, IFN-independent activation of canonically IFN-dependent signaling pathways has also been documented, such as IFN-independent biphasic activation of signal transducer and activator of transcription 1 (STAT1) during infection of monocytes, differential roles of mitochondrial and peroxisomal mitochondrial antiviral-signaling protein (MAVS), and the ability of human CMV (HCMV) immediate early protein 1 (IE1) protein to reroute IL-6 signaling and activation of STAT1 and its associated ISGs. This review examines the role of identified IFN-independent ISGs in the antiviral response to CMV and describes pathways of IFN-independent innate immune response induction by CMV.
- Published
- 2019
- Full Text
- View/download PDF
8. Interferon-Independent Upregulation of Interferon-Stimulated Genes during Human Cytomegalovirus Infection is Dependent on IRF3 Expression
- Author
-
Caroline L. Ashley, Allison Abendroth, Brian P. McSharry, and Barry Slobedman
- Subjects
interferon ,human cytomegalovirus ,IRF3 ,ISG15 ,interferon stimulated genes ,Microbiology ,QR1-502 - Abstract
The antiviral activity of type I interferons (IFNs) is primarily mediated by interferon-stimulated genes (ISGs). Induction of ISG transcription is achieved when type I IFNs bind to their cognate receptor and activate the Janus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT) signaling pathways. Recently it has become clear that a number of viruses are capable of directly upregulating a subset of ISGs in the absence of type I IFN production. Using cells engineered to block either the response to, or production of type I IFN, the regulation of IFN-independent ISGs was examined in the context of human cytomegalovirus (HCMV) infection. Several ISGs, including IFIT1, IFIT2, IFIT3, Mx1, Mx2, CXCL10 and ISG15 were found to be upregulated transcriptionally following HCMV infection independently of type I IFN-initiated JAK-STAT signaling, but dependent on intact IRF3 signaling. ISG15 protein regulation mirrored that of its transcript with IFNβ neutralization failing to completely inhibit ISG15 expression post HCMV infection. In addition, no detectable ISG15 protein expression was observed following HCMV infection in IRF3 knockdown CRISPR/Cas-9 clones indicating that IFN-independent control of ISG expression during HCMV infection of human fibroblasts is absolutely dependent on IRF3 expression.
- Published
- 2019
- Full Text
- View/download PDF
9. A unique cytotoxic CD4+T cells signature defines critical COVID-19
- Author
-
Sarah Baird, Caroline L. Ashley, Felix Marsh-Wakefield, Sibel Alca, Thomas M. Ashhurst, Angela L. Ferguson, Hannah Lukeman, Claudio Counoupas, Jeffrey J. Post, Pamela Konecny, Adam Bartlett, Marianne Martinello, Rowena A. Bull, Andrew Lloyd, Alice Grey, Owen Hutchings, Umaimainthan Palendira, Warwick J. Britton, Megan Steain, and James A. Triccas
- Abstract
Background and objectivesSARS-CoV-2 infection causes a spectrum of clinical disease presentation, ranging from asymptomatic to fatal. While neutralising antibody (NAb) responses correlate with protection against symptomatic and severe infection, the contribution of the T cell response to the resolution or progression of disease is still unclear. Optimal protective immunity may require activation of distinct immune pathways. As such, defining the contribution of individual T cell subsets to disease outcome is imperative to inform the development of next-generation COVID-19 vaccines. To address this, we performed immunophenotyping of T cell responses in unvaccinated individuals, representing the full spectrum of COVID-19 clinical presentation.MethodsSpectral cytometry was performed on peripheral blood mononuclear cell samples from patients with PCR-confirmed SARS-CoV-2 infection. Computational and manual analyses were used to identify T cell populations associated with distinct disease states through unbiased clustering, principal component analysis and discriminant analysis.ResultsCritical SARS-CoV-2 infection was characterised by an increase in activated and cytotoxic CD4+(CTL) cells of a T follicular helper (TFH) or effector memory re-expressing CD45RA (TEMRA) phenotype. These CD4+CTLs were largely absent in those with less severe disease. In contrast, those with asymptomatic or mild disease were associated with high proportions of naïve T cells and reduced expression of activation markers.ConclusionHighly activated and cytotoxic CD4+T cell responses may contribute to cell-mediated host tissue damage and progression of COVID-19. Potential for induction of these detrimental T cell responses should be considered when developing and implementing effective COVID-19 control strategies.
- Published
- 2023
10. Discovery of Cyclic Peptide Ligands to the SARS-CoV‑2 Spike Protein Using mRNA Display
- Author
-
Anneliese S. Ashhurst, Caroline L. Ashley, K. Patel, Mary Christie, Anupriya Aggarwal, Charlotte Franck, Paige M. E. Hawkins, Alex Norman, Toby Passioura, James A. Triccas, Stuart Turville, Joel P. Mackay, Richard J. Payne, Jason Low, Megan Steain, and Rezwan Siddiquee
- Subjects
General Chemical Engineering ,010402 general chemistry ,medicine.disease_cause ,01 natural sciences ,Affinity Reagent ,medicine ,Molecule ,mRNA display ,Binding site ,Beta (finance) ,QD1-999 ,Coronavirus ,chemistry.chemical_classification ,010405 organic chemistry ,Chemistry ,COVID-19 ,General Chemistry ,Ligand (biochemistry) ,Cyclic peptide ,0104 chemical sciences ,Dissociation constant ,Biochemistry ,Biophysics ,03 Chemical Sciences ,Research Article - Abstract
The COVID-19 pandemic, caused by SARS-CoV-2, has led to substantial morbidity, mortality, and disruption globally. Cellular entry of SARS-CoV-2 is mediated by the viral spike protein, and affinity ligands to this surface protein have the potential for applications as antivirals and diagnostic reagents. Here, we describe the affinity selection of cyclic peptide ligands to the SARS-CoV-2 spike protein receptor binding domain (RBD) from three distinct libraries (in excess of a trillion molecules each) by mRNA display. We identified six high affinity molecules with dissociation constants (KD) in the nanomolar range (15–550 nM) to the RBD. The highest affinity ligand could be used as an affinity reagent to detect the spike protein in solution by ELISA, and the cocrystal structure of this molecule bound to the RBD demonstrated that it binds to a cryptic binding site, displacing a β-strand near the C-terminus. Our findings provide key mechanistic insight into the binding of peptide ligands to the SARS-CoV-2 spike RBD, and the ligands discovered in this work may find future use as reagents for diagnostic applications., We describe the discovery of high affinity ligands to the SARS-CoV-2 spike protein receptor binding domain using RaPID mRNA display and demonstrate their utility for viral detection by ELISA.
- Published
- 2021
11. Neutralising antibodies against the SARS-CoV-2 Delta variant induced by Alhydroxyquim-II-adjuvanted trimeric spike antigens
- Author
-
Florian M. Wurm, Paco Pino, Stuart Turville, Maria J Wurm, Megan Steain, Charles Metayer, Jacopo Martinis, Sunil A. David, Claudio Counoupas, Alberto Ospina Stella, Caroline L. Ashley, James A. Triccas, Anupriya Aggarwal, Hannah Lukeman, Nayan D. Bhattacharyya, Joeri Kint, Nathaniel R. Landau, Takuya Tada, Belinda M Dcosta, and Stephanie Anchisi
- Subjects
Agonist ,medicine.drug_class ,Protein subunit ,COVID-19 ,TLR7 ,Biology ,medicine.disease_cause ,Virology ,Vaccination ,Coronavirus ,Antigen ,1107 Immunology ,medicine ,biology.protein ,Antibody ,Beta (finance) ,11 Medical and Health Sciences - Abstract
Global control of COVID-19 will require the deployment of vaccines capable of inducing long-term protective immunity against SARS-CoV-2 variants. In this report, we describe an adjuvanted subunit candidate vaccine that affords elevated, sustained and cross-variant SARS-CoV-2 neutralising antibodies (NAbs) in multiple animal models. Alhydroxiquim-II is a TLR7/8 small-molecule agonist chemisorbed on aluminium hydroxide. Vaccination with Alhydroxiquim-II combined with a stabilized, trimeric form of the SARS-CoV-2 spike protein (termed CoVac-II) resulted in high-titre NAbs in mice, with no decay in responses over an 8-month period. NAbs from sera of CoVac-II-immunized mice, horses and rabbits were broadly neutralising against SARS-CoV-2 variants. Boosting long-term CoVac-II-immunized mice with adjuvanted spike protein from the Beta variant markedly increased levels of NAb titres against multiple SARS-CoV-2 variants; notably high titres against the Delta variant were observed. These data strongly support the clinical assessment of Alhydroxiquim-II-adjuvanted spike proteins to protect against SARS-CoV-2 variants of concern.
- Published
- 2021
12. Interferon-Independent Upregulation of Interferon-Stimulated Genes during Human Cytomegalovirus Infection is Dependent on IRF3 Expression
- Author
-
Barry Slobedman, Brian P. McSharry, Allison Abendroth, and Caroline L. Ashley
- Subjects
0301 basic medicine ,Human cytomegalovirus ,ISG15 ,viruses ,lcsh:QR1-502 ,Cytomegalovirus ,Biology ,Real-Time Polymerase Chain Reaction ,lcsh:Microbiology ,Article ,03 medical and health sciences ,Interferon ,Virology ,medicine ,Humans ,Ubiquitins ,Cells, Cultured ,Gene knockdown ,030102 biochemistry & molecular biology ,interferon stimulated genes ,virus diseases ,Interferon-beta ,interferon ,Fibroblasts ,IRF3 ,medicine.disease ,Immunity, Innate ,3. Good health ,Cell biology ,Up-Regulation ,030104 developmental biology ,Infectious Diseases ,HEK293 Cells ,human cytomegalovirus ,Gene Knockdown Techniques ,STAT protein ,Cytokines ,Interferon Regulatory Factor-3 ,Interferons ,Signal transduction ,Janus kinase ,medicine.drug ,Signal Transduction - Abstract
The antiviral activity of type I interferons (IFNs) is primarily mediated by interferon-stimulated genes (ISGs). Induction of ISG transcription is achieved when type I IFNs bind to their cognate receptor and activate the Janus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT) signaling pathways. Recently it has become clear that a number of viruses are capable of directly upregulating a subset of ISGs in the absence of type I IFN production. Using cells engineered to block either the response to, or production of type I IFN, the regulation of IFN-independent ISGs was examined in the context of human cytomegalovirus (HCMV) infection. Several ISGs, including IFIT1, IFIT2, IFIT3, Mx1, Mx2, CXCL10 and ISG15 were found to be upregulated transcriptionally following HCMV infection independently of type I IFN-initiated JAK-STAT signaling, but dependent on intact IRF3 signaling. ISG15 protein regulation mirrored that of its transcript with IFN&beta, neutralization failing to completely inhibit ISG15 expression post HCMV infection. In addition, no detectable ISG15 protein expression was observed following HCMV infection in IRF3 knockdown CRISPR/Cas-9 clones indicating that IFN-independent control of ISG expression during HCMV infection of human fibroblasts is absolutely dependent on IRF3 expression.
- Published
- 2019
13. Virus-Mediated Suppression of the Antigen Presentation Molecule MR1
- Author
-
Jose A Villadangos, Megan Steain, Carolyn Samer, Jamie Rossjohn, David P. Fairlie, Paul R. Kinchington, James McCluskey, Michael B. Yee, Ligong Liu, Barry Slobedman, Brian P. McSharry, Allison Abendroth, Hamish E G McWilliam, and Caroline L. Ashley
- Subjects
0301 basic medicine ,Gene Expression Regulation, Viral ,Male ,viruses ,Antigen presentation ,Cytomegalovirus ,Herpesvirus 1, Human ,Protein Serine-Threonine Kinases ,medicine.disease_cause ,Ligands ,Jurkat cells ,General Biochemistry, Genetics and Molecular Biology ,Virus ,Article ,Mucosal-Associated Invariant T Cells ,Cell Line ,Minor Histocompatibility Antigens ,03 medical and health sciences ,Jurkat Cells ,Viral Proteins ,0302 clinical medicine ,Downregulation and upregulation ,medicine ,Humans ,lcsh:QH301-705.5 ,Regulation of gene expression ,Antigen Presentation ,Chemistry ,T-cell receptor ,Cell Membrane ,Histocompatibility Antigens Class I ,Fibroblasts ,Cell biology ,030104 developmental biology ,Herpes simplex virus ,lcsh:Biology (General) ,Cell culture ,Proteolysis ,Female ,Proteasome Inhibitors ,030217 neurology & neurosurgery - Abstract
SUMMARY The antigen-presenting molecule MR1 presents microbial metabolites related to vitamin B2 biosynthesis to mucosal-associated invariant T cells (MAIT cells). Although bacteria and fungi drive the MR1 biosynthesis pathway, viruses have not previously been implicated in MR1 expression or its antigen presentation. We demonstrate that several herpesviruses inhibit MR1 cell surface upregulation, including a potent inhibition by herpes simplex virus type 1 (HSV-1). This virus profoundly suppresses MR1 cell surface expression and targets the molecule for proteasomal degradation, whereas ligand-induced cell surface expression of MR1 prior to infection enables MR1 to escape HSV-1-dependent targeting. HSV-1 downregulation of MR1 is dependent on de novo viral gene expression, and we identify the Us3 viral gene product as functioning to target MR1. Furthermore, HSV-1 downregulation of MR1 disrupts MAIT T cell receptor (TCR) activation. Accordingly, virus-mediated targeting of MR1 defines an immunomodulatory strategy that functionally disrupts the MR1-MAIT TCR axis., Graphical Abstract, In Brief The antigen-presenting molecule MR1 presents bacterial and fungal metabolites to MAIT cells. McSharry et al. show that the herpesviruses HSV-1 and CMV disrupt MR1 expression. Downregulation of MR1 by HSV-1 inhibits bacterially driven MAIT TCR-dependent activation. This provides evidence of virus immunomodulatory control of the MR1-restricted immune response.
- Published
- 2020
14. Nuclear domain 10 components upregulated via interferon during human cytomegalovirus infection potently regulate viral infection
- Author
-
Allison Abendroth, Barry Slobedman, Brian P. McSharry, Mandy Glass, and Caroline L. Ashley
- Subjects
0301 basic medicine ,Human cytomegalovirus ,Gene Expression Regulation, Viral ,viruses ,Cytomegalovirus ,Biology ,Promyelocytic Leukemia Protein ,Autoantigens ,Cell Line ,03 medical and health sciences ,Promyelocytic leukemia protein ,Downregulation and upregulation ,RNA interference ,Interferon ,Virology ,medicine ,Humans ,RNA, Small Interfering ,Adaptor Proteins, Signal Transducing ,Regulation of gene expression ,Gene knockdown ,Innate immune system ,virus diseases ,Nuclear Proteins ,Antigens, Nuclear ,Interferon-beta ,biochemical phenomena, metabolism, and nutrition ,medicine.disease ,Immunity, Innate ,Up-Regulation ,030104 developmental biology ,HEK293 Cells ,Cytomegalovirus Infections ,biology.protein ,RNA Interference ,Co-Repressor Proteins ,medicine.drug ,Molecular Chaperones - Abstract
Human cytomegalovirus (HCMV) is a ubiquitous betaherpesvirus that causes life-threatening disease in immunocompromised and immunonaive individuals. Type I interferons (IFNs) are crucial molecules in the innate immune response to HCMV and are also known to upregulate several components of the interchromosomal multiprotein aggregates collectively referred to as nuclear domain 10 (ND10). In the context of herpesvirus infection, ND10 components are known to restrict gene expression. This raises the question as to whether key ND10 components (PML, Sp100 and hDaxx) act as anti-viral IFN-stimulated genes (ISGs) during HCMV infection. In this study, analysis of ND10 component transcription during HCMV infection demonstrated that PML and Sp100 were significantly upregulated whilst hDaxx expression remained unchanged. In cells engineered to block the production of, or response to, type I IFNs, upregulation of PML and Sp100 was not detected during HCMV infection. Furthermore, pre-treatment with an IFN-β neutralizing antibody inhibited upregulation of PML and Sp100 during both infection and treatment with HCMV-infected cell supernatant. The significance of ND10 components functioning as anti-viral ISGs during HCMV infection was determined through knockdown of PML, Sp100 and hDaxx. ND10 knockdown cells were significantly more permissive to HCMV infection, as previously described but, in contrast to control cells, could support HCMV plaque formation following IFN-β pre-treatment. This ability of HCMV to overcome the potently anti-viral effects of IFN-β in ND10 expression deficient cells provides evidence that ND10 component upregulation is a key mediator of the anti-viral activity of IFN-β.
- Published
- 2017
15. A unique cytotoxic CD4+ T cell‐signature defines critical COVID‐19
- Author
-
Sarah Baird, Caroline L Ashley, Felix Marsh‐Wakefield, Sibel Alca, Thomas M Ashhurst, Angela L Ferguson, Hannah Lukeman, Claudio Counoupas, Jeffrey J Post, Pamela Konecny, Adam Bartlett, Marianne Martinello, Rowena A Bull, Andrew Lloyd, Alice Grey, Owen Hutchings, Umaimainthan Palendira, Warwick J Britton, Megan Steain, and James A Triccas
- Subjects
CD4‐CTLs ,COVID‐19 ,SARS‐CoV‐2 ,spectral cytometry ,T cells ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Abstract Objectives SARS‐CoV‐2 infection causes a spectrum of clinical disease presentation, ranging from asymptomatic to fatal. While neutralising antibody (NAb) responses correlate with protection against symptomatic and severe infection, the contribution of the T‐cell response to disease resolution or progression is still unclear. As newly emerging variants of concern have the capacity to partially escape NAb responses, defining the contribution of individual T‐cell subsets to disease outcome is imperative to inform the development of next‐generation COVID‐19 vaccines. Methods Immunophenotyping of T‐cell responses in unvaccinated individuals was performed, representing the full spectrum of COVID‐19 clinical presentation. Computational and manual analyses were used to identify T‐cell populations associated with distinct disease states. Results Critical SARS‐CoV‐2 infection was characterised by an increase in activated and cytotoxic CD4+ lymphocytes (CTL). These CD4+ CTLs were largely absent in asymptomatic to severe disease states. In contrast, non‐critical COVID‐19 was associated with high frequencies of naïve T cells and lack of activation marker expression. Conclusion Highly activated and cytotoxic CD4+ T‐cell responses may contribute to cell‐mediated host tissue damage and progression of COVID‐19. Induction of these potentially detrimental T‐cell responses should be considered when developing and implementing effective COVID‐19 control strategies.
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.